Dr. Yaojun Zhang 张耀军
Chief Physician
Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive and comprehensive treatment of early-stage liver cancer, including radiofrequency ablation, surgical resection, interventional therapy, and targeted therapy.
Dr. Zhang holds a PhD in Clinical Oncology from Sun Yat-sen University Cancer Center (SYSUCC). Since 2002, Dr. Zhang has specialized in liver cancer care. Training includes roles at SYSUCC and visiting scholar positions at The Chinese University of Hong Kong (2007) and Imperial College London (2011). Research contributions received awards from the Guangdong Provincial Government, China Anti-Cancer Association, and Chinese Medical Association. Dr. Zhang has published over 20 SCI papers in the past three years.
Name order: in Chinese the family name comes first (Zhang Yaojun). Papers usually list the name as Yaojun Zhang or Zhang Y.
Selected publications
179 papers on PubMed matched by name and affiliation; 36 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Clin Oncol, 2025 (senior author): Reply to: Importance of Defining Recurrence in Hepatocellular Carcinoma: Local or Both Local and Other Intrahepatic Recurrences?. PubMed 40132143
- Int J Surg, 2025 (senior author): Neoadjuvant hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for resectable single large hepatocellular carcinoma. PubMed 40358645
- J Clin Oncol, 2025 (senior author): Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial. PubMed 39693584
- Radiology, 2025 (first author): Transarterial Chemoembolization with Radiofrequency Ablation versus Surgical Resection for Small Late-Recurrence Hepatocellular Carcinoma. PubMed 39903071
- Int J Surg, 2025 (senior author): Comparison of resection, ablation, and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤5 cm: a retrospective, multicenter, cohort study. PubMed 39093867
- Int J Surg, 2025 (senior author): Dynamic changes of serum α-fetoprotein predict the prognosis of bevacizumab plus immunotherapy in hepatocellular carcinoma. PubMed 38905506
- ILIVER, 2024 (senior author): Gd-EOB-DTPA-enhanced MRI proves advantageous in selecting surgical candidates for patients with early-stage hepatocellular carcinoma: An analysis in terms of oncological outcomes. PubMed 40635860
- Front Immunol, 2024 (senior author): Efficacy and safety of atezolizumab-bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study. PubMed 39628474
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion